RGLS insider transaction filings

Regulus Therapeutics Inc. — 27 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-06-27. Screen RGLS transaction legs live →

FiledFormInsiderReported transactionsSource
2025-06-274Witz Pascale — DirectorDisposition to issuer (D): 67,233 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 2,325 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · +4 moreEDGAR
2025-06-274Rosen Hugh — DirectorCode (U): 6,979 · Disposition to issuer (D): 57,292 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 2,325 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · +4 moreEDGAR
2025-06-274Aker Christopher Ray — Sr. VP & General CounselCode (U): 60,796 · Disposition to issuer (D): 83,125 · Disposition to issuer (D): 2,500 (derivative) · Disposition to issuer (D): 750 (derivative) · Disposition to issuer (D): 33,500 (derivative) · Disposition to issuer (D): 21,000 (derivative) · +7 moreEDGAR
2025-06-274Huang Alice Shih-hou — DirectorCode (U): 5,208 · Disposition to issuer (D): 57,292 · Code (U): 27,377 · Disposition to issuer (D): 57,292 · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · +12 moreEDGAR
2025-06-274Collier Kathryn J — DirectorDisposition to issuer (D): 75,565 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · +1 moreEDGAR
2025-06-274CALSADA CRISPINA — Chief Financial OfficerDisposition to issuer (D): 140,228 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 21,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · +5 moreEDGAR
2025-06-274Klassen Preston — President & Head of R & D, DirectorDisposition to issuer (D): 115,555 · Disposition to issuer (D): 350,000 (derivative) · Disposition to issuer (D): 225,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 528,000 (derivative) · Disposition to issuer (D): 675,000 (derivative)EDGAR
2025-06-274Hagan Joseph P — Chief Executive Officer, DirectorDisposition to issuer (D): 571,558 · Disposition to issuer (D): 6,500 (derivative) · Disposition to issuer (D): 1,000 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 90,000 (derivative) · Disposition to issuer (D): 160,000 (derivative) · +7 moreEDGAR
2025-06-274Nunn Jason Raleigh — DirectorDisposition to issuer (D): 62,500 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 2,325 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · +3 moreEDGAR
2025-06-274RASTETTER WILLIAM H — DirectorCode (U): 44,264 · Disposition to issuer (D): 57,292 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 2,325 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · +4 moreEDGAR
2025-06-274PAPADOPOULOS STELIOS — DirectorCode (U): 976,253 · Disposition to issuer (D): 64,635 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 2,325 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · +5 moreEDGAR
2025-06-274BALTIMORE DAVID — DirectorCode (U): 27,377 · Disposition to issuer (D): 57,292 · Code (U): 5,208 · Disposition to issuer (D): 57,292 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 2,325 (derivative) · +12 moreEDGAR
2025-06-184Collier Kathryn J — DirectorOption exercise (M): 1,396 @ $9.90 · Option exercise (M): 2,604 @ $9.90 · Option exercise (M): 2,325 @ $8.80 · Option exercise (M): 1,396 (derivative) @ $0 · Option exercise (M): 2,604 (derivative) @ $0 · Option exercise (M): 2,325 (derivative) @ $0EDGAR
2025-06-044Klassen Preston — President & Head of R & D, DirectorPurchase (P): 12,000 @ $7.99EDGAR
2025-04-304Huang Alice Shih-hou — DirectorGrant/award (A): 62,500 @ $0 · Grant/award (A): 62,500 @ $0EDGAR
2025-04-304Witz Pascale — DirectorGrant/award (A): 62,500 @ $0EDGAR
2025-04-304Collier Kathryn J — DirectorGrant/award (A): 62,500 @ $0EDGAR
2025-04-304Rosen Hugh — DirectorGrant/award (A): 62,500 @ $0EDGAR
2025-04-304Nunn Jason Raleigh — DirectorGrant/award (A): 62,500 @ $0EDGAR
2025-04-304RASTETTER WILLIAM H — DirectorGrant/award (A): 62,500 @ $0EDGAR
2025-04-304PAPADOPOULOS STELIOS — DirectorGrant/award (A): 62,500 @ $0EDGAR
2025-04-304BALTIMORE DAVID — DirectorGrant/award (A): 62,500 @ $0 · Grant/award (A): 62,500 @ $0EDGAR
2025-01-314Aker Christopher Ray — Sr. VP & General CounselGrant/award (A): 487,500 (derivative) @ $0EDGAR
2025-01-314CALSADA CRISPINA — Chief Financial OfficerGrant/award (A): 562,500 (derivative) @ $0EDGAR
2025-01-314Klassen Preston — President & Head of R & D, DirectorGrant/award (A): 675,000 (derivative) @ $0EDGAR
2025-01-314Hagan Joseph P — Chief Executive Officer, DirectorPurchase (P): 50,000 @ $1.09 · Grant/award (A): 1,350,000 (derivative) @ $0EDGAR
2025-01-314BALTIMORE DAVID — DirectorPurchase (P): 19,610 @ $1.06EDGAR

Recent 8-K events — Regulus Therapeutics Inc.

FiledFormItems reportedSource
2025-06-258-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2025-05-088-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-04-308-K1.01 — Entry into a Material Definitive Agreement
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-03-278-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-03-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-03-048-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=RGLS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →